← Back to Search

Radiation Therapy

Stereotactic Ablative Body Radiation (SABR) for Lung Cancer

Phase 1
Waitlist Available
Led By Tim Lautenschlaeger, MD
Research Sponsored by Indiana University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial is testing whether 5 fraction SABR is safe and improves local control for early stage squamous cell carcinoma of the lung, compared to the current standard of 4 or 5 fractions.

Eligible Conditions
  • Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rate of dose limiting toxicities (DLTs) in each cohort during Phase 1
Secondary outcome measures
Local control during Phase 2
Overall survival

Trial Design

5Treatment groups
Experimental Treatment
Group I: Phase 2Experimental Treatment1 Intervention
The maximum tolerated radiation dose determined during Phase 1 (i.e. 11, 12, 13, or 14 Gy) will be given in 5 fractions for a total dose of 55, 60, 65, or 70 Gy.
Group II: Phase 1/Dose Level 4Experimental Treatment1 Intervention
14 Gy will be given in 5 fractions for a total dose of 70 Gy
Group III: Phase 1/Dose Level 3Experimental Treatment1 Intervention
13 Gy will be given in 5 fractions for a total dose of 65 Gy
Group IV: Phase 1/Dose Level 2Experimental Treatment1 Intervention
12 Gy will be given in 5 fractions for a total dose of 60 Gy
Group V: Phase 1/Dose Level 1Experimental Treatment1 Intervention
11 Gy will be given in 5 fractions for a total dose of 55 Gy

Find a Location

Who is running the clinical trial?

Indiana University School of MedicineOTHER
185 Previous Clinical Trials
142,780 Total Patients Enrolled
Indiana UniversityLead Sponsor
980 Previous Clinical Trials
983,288 Total Patients Enrolled
Tim Lautenschlaeger, MDPrincipal InvestigatorIndiana University
1 Previous Clinical Trials

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung
Tim Lautenschlaeger 2017. "Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03321747.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top